|
|
|
News Releases |
 |
All Releases
 |
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2009 and Provides Outlook for 2010
Mar 8, 2010
|
22.6 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Mar 8, 2010 (Canada NewsWire via COMTEX News Network) -- Conference Call on Monday, March 8, 2010 at 4:30 p.m. Eastern Time
OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI), today announced its fourth quarter and fiscal year 2009 financial results, reviewed the Company's highlights and pr...
|
|
OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Mar 4, 2010
|
12.1 KB |
|
| |
BOTHELL, WA and VANCOUVER, WA, Mar 4, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and fiscal year 2009 financial results will be released at the market close on Monday, March 8, 2010, and that the Company will host a conference call and live webca...
|
|
Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer
Mar 1, 2010
|
16.5 KB |
|
| |
BOTHELL, WA and VANCOUVER, Mar 1, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor ...
|
|
OncoGenex Pharmaceuticals to Present at RBC Capital Markets' Healthcare Conference
Mar 1, 2010
|
11.9 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Mar 1, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the RBC Capital Markets' Healthcare Conference on a panel titled "Cancer: Improving Treatment Through Combination T...
|
|
The European Medicines Agency is in Overall Agreement with OncoGenex Pharmaceuticals' Development Plan for OGX-011 in Patients with Metastatic Castrate-Resistant Prostate Cancer
Feb 25, 2010
|
15.9 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Feb. 25, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic c...
|
|
OncoGenex Announces Departure of Chief Financial Officer
Feb 25, 2010
|
13.6 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Feb. 25, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company and Steve Anderson, its chief financial officer, have agreed that he will leave the Company effective yesterday.
OncoGenex has initiated an executive search to identify a CFO c...
|
|
OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding
Jan 6, 2010
|
16.7 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Jan. 6, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has rec...
|
|
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Dec 21, 2009
|
20.2 KB |
|
| |
JERUSALEM, Israel, BOTHELL, WA and VANCOUVER, Canada, Dec. 21, 2009 (Canada NewsWire via COMTEX News Network) -- -- Phase III trials of OGX-011 in first- and second-line advanced prostate cancer and non-small cell lung cancer, expected to begin in 2010 and early 2011 --
-- Significantly strengthens Teva's oncology offerings with novel therapeut...
|
|
OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
Dec 20, 2009
|
12.1 KB |
|
| |
BOTHELL, WA and VANCOUVER, BC, Dec. 20, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will host a conference call at 8:30 a.m. Eastern Time on Monday, December 21, 2009.
A live webcast will be available through the Investor Relations page of the OncoGenex Web si...
|
|
OncoGenex Reports Third Quarter 2009 Financial Results
Nov 5, 2009
|
21.3 KB |
|
| |
BOTHELL, WA and VANCOUVER Nov. 5, 2009 (Canada NewsWire via COMTEX News Network) -- Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time
OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and re...
|
|
OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
Nov 2, 2009
|
12.7 KB |
|
| |
BOTHELL, WA and VANCOUVER Nov. 2, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will announce third quarter financial results after the market closes on Thursday, November 5, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. ET that afternoon...
|
|
OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category
Oct 9, 2009
|
14.1 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Oct. 9, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award...
|
|
FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy
Oct 6, 2009
|
15.1 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Oct. 6, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with...
|
|
OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Sep 3, 2009
|
12.0 KB |
|
| |
BOTHELL, WA and VANCOUVER, Sep. 3, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company will webcast presentations at the following investor conferences:
...
|
|
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
Aug 13, 2009
|
15.7 KB |
|
| |
BOTHELL, WA and VANCOUVER, Aug. 13, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer. This tri...
|
|
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
Aug 10, 2009
|
14.5 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Aug. 10, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotid...
|
|
OncoGenex Reports Second Quarter 2009 Financial Results
Aug 6, 2009
|
20.5 KB |
|
| |
BOTHELL, WA, and VANCOUVER, Aug. 6, 2009 (Canada NewsWire via COMTEX News Network) --
>
OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the second quarter and six months ended ...
|
|
OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Aug 3, 2009
|
12.1 KB |
|
| |
BOTHELL, WA and VANCOUVER, Aug. 3, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company will announce second quarter financial results on Thursday, August 6, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. EDT that afternoon to discuss quarterly results...
|
|
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Jul 24, 2009
|
14.4 KB |
|
| |
BOTHELL, WA and VANCOUVER, Jul 24, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has completed its registered direct offering, previously announced on July 20, 2009, of 475,000 shares of its common stock to institutional investors at a price of $20.00 per share, for gross pr...
|
|
OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
Jul 20, 2009
|
14.0 KB |
|
| |
BOTHELL, WA and VANCOUVER, Jul 20, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today it has entered into purchase agreements with certain institutional investors for the sale of 475,000 shares of its common stock at a price of $20 per share through a registered direct offering. The tran...
|
|
|
= add release to Briefcase
|
|
|
|
1.29
